Skip to content

China Multi-Center Cohort Study on Risk Evaluation of Heart Failure: The ChinaCORE HF Registry

China Multi-Center Cohort Study on Risk Evaluation of Heart Failure: The ChinaCORE HF Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115852
Enrollment
Unknown
Registered
2025-12-31
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Heart failure patients:N/A

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 80 years; (2) Meeting the diagnostic criteria for heart failure according to the latest international and national authoritative guidelines, including the following three categories of patients:     HFrEF: heart failure with reduced ejection fraction, LVEF =50%, accompanied by diastolic dysfunction (e.g., E/e' >15); (3) Clear consciousness, able to understand the study procedures, capable of providing written informed consent, and demonstrating good treatment adherence.

Exclusion criteria

Exclusion criteria: (1) Age 80 years; (2) Patients with severe hepatic or renal dysfunction, malignancy, or severe infection; (3) Inability to obtain valid blood samples; (4) Pregnant or lactating women; (5) Individuals lacking legal capacity or with limited legal capacity, or any other condition deemed by the investigators to make participation in this clinical study inappropriate.

Design outcomes

Primary

MeasureTime frame
All-cause mortality: death from any cause during the follow-up period.;Cardiovascular events: including heart failure rehospitalization (hospitalization due to worsening heart failure symptoms), acute myocardial infarction (meeting the Universal Definition of Myocardial Infarction), and stroke (imaging-confirmed ischemic or hemorrhagic stroke).;

Secondary

MeasureTime frame
Worsening of cardiac function: an increase of =1 class in New York Heart Association (NYHA) functional classification, or a decrease in left ventricular ejection fraction (LVEF) of =10% from baseline.;Drug responsiveness: therapeutic effects (e.g., symptom improvement, increase in LVEF) or adverse reactions (e.g., hypotension, deterioration of renal function) to heart failure medications such as ß-blockers or ACE inhibitors.;

Countries

China

Contacts

Public ContactLiang Chen

Fuwai Hospital, Chinese Academy of Medical Sciences

chenliang_2012@126.com+86 188 0016 1266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026